[Evaluation on the safety and immunogenicity of Canada split influenza virus vaccine].
OBJECTIVE
To evaluate the safety and immunogenicity of Canada split influenza virus vaccine.


METHODS
Cluster samples were by randomly chosen and divided into split vaccination group and homoimported influenza vaccination group.


RESULTS
After injection, fever-reaction and local reaction rates of 'trial' group were found as 3.69% and 1.75% respectively, but no statistical significance was found when compared with 'control' group. However the antibody positive rates of 'trail' and 'control' groupsappeared statistically significant (H1N1: 96.8% vs. 92.3%, H3N2: 95.8% vs. 90.2%, B: 52.3% vs. 62.3%). For geometric mean titer (GMT) of type H1N1, H3H2 and B antibody, 'trial' group and 'control' group increased 22.4, 16.8, 8.2 and 21.2, 12.5 and 7.4 times respectively. The antibody protective rates of type H1N1, H3N2 and B were 99%, 99% and 53.9% for 'trial' group, and 96.2%, 98.4% and 62.3% for 'control' but with no statistically significant difference.


CONCLUSIONS
Influenza split vaccine made in Shire company in Canada was safe and with good immunogenicity.
Hu
Yue-mei
YM
Jiangsu Provincial Center of Disease Control and Prevention, Nanjing 210009, China.
Fang
Han-hua
HH
Gao
Gui-hua
GH
Zhang
Xue-feng
XF
Zhang
Yi-ju
YJ
Zhu
Shi-wei
SW
Zhu
Feng-cai
FC
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000917:Antibody Formation / Q000276:immunology; D002170:Canada; D002648:Child; D002675:Child, Preschool; D064420:Drug-Related Side Effects and Adverse Reactions / Q000276:immunology*; D005260:Female; D006801:Humans; D007223:Infant; D007267:Injections; D008297:Male; D008875:Middle Aged; D009975:Orthomyxoviridae / Q000276:immunology*; D013997:Time Factors; D014765:Viral Vaccines / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology*; D055815:Young Adult
D014765:Viral Vaccines